medigraphic.com

2022, Number 3

<< Back Next >>

Rev Educ Bioquimica 2022; 41 (3)

Ascitis en cáncer de ovario y la ley de starling

Arechavaleta-Velasco F, Olivares A, Díaz-Cueto L

Language: Spanish
References: 54
Page: 85-95
PDF size: 359.24 Kb.


ABSTRACT

Ascites in ovarian cancer is the accumulation of fluid in the abdominal or peritoneal cavity due to an alteration in the capillaries’ hemodynamics. Ascites formation is determined by Starling’s law, which establishes that the exchange of fluids between the plasma and the interstitial space depends on the hydrostatic and oncotic pressure established in the capillary wall. Also, proteins and other factors in the ascites fluid contribute to its formation by altering capillaries’ permeability, filtration surface area, hydrostatic and oncotic pressure difference. Ascites fluid promotes tumor dissemination since advanced stages of ovarian carcinoma (III and IV) are associated with large volumes of malignant ascites and peritoneal cancerous implants. Primary surgery and chemotherapy are the major options for ovarian cancer treatment; however, paracentesis (drainage of ascites fluid) is necessary for some patients. Nowadays, new alternatives for ovarian cancer treatment are being pursued, and given the characteristics of ascites in this disease, preventing its formation could be beneficial for the patients. Therefore, this article reviews the formation and composition of ascites in ovarian cancer and its importance in new strategies for developing novel treatments for this disease.


REFERENCES

  1. Sung H. Ferlay J. Siegel RL. LaversanneM. Soerjomataram I. Jemal A. et al. GlobalCancer Statistics 2020: GLOBOCAN Estimatesof Incidence and Mortality Worldwide for 36Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209-249.

  2. Prat J. D’Angelo E. Espinosa I. Ovariancarcinomas: at least five different diseases withdistinct histological features and moleculargenetics. Hum Pathol. 2018; 80:11-27.

  3. Torre LA. Trabert B. DeSantis CE. Miller KD.Samimi G. Runowicz CD. et al. Ovarian cancerstatistics, 2018. CA Cancer J Clin. 2018;68:284-296.

  4. Kehoe S. FIGO staging in ovarian carcinomaand histological subtypes. J Gynecol Oncol.2020; 31:e70.

  5. Adam RA. Adam YG. Malignant ascites: past,present, and future. J Am Coll Surg. 2004;198:999-1011.

  6. Rickard BP. Conrad C. Sorrin AJ. Ruhi MK.Reader JC. Huang SA. et al. MalignantAscites in Ovarian Cancer: Cellular, Acellular,and Biophysical Determinants of MolecularCharacteristics and Therapy Response.Cancers (Basel). 2021; 13:4318.

  7. Press JZ. Reyes M. Pitteri SJ. Pennil C. GarciaR. Goff BA. et al. Microparticles from ovariancarcinomas are shed into ascites and promotecell migration. Int J Gynecol Cancer. 2012;22:546-552.

  8. Woopen H. Sehouli J. Current and futureoptions in the treatment of malignant ascitesin ovarian cancer. Anticancer Res. 2009;29:3353-3359.

  9. Ahmed N. Stenvers KL. Getting to KnowOvarian Cancer Ascites: Opportunitiesfor Targeted Therapy-Based TranslationalResearch. Front Oncol. 2013; 3:256.

  10. Renkin EM. Some consequences of capillarypermeability to macromolecules: Starling’shypothesis reconsidered. Am J Physiol. 1986;250:H706-10.

  11. Tamsma JT. Keizer HJ. Meinders AE.Pathogenesis of malignant ascites: Starling’slaw of capillary hemodynamics revisited. AnnOncol. 2001; 12:1353-1357.

  12. Braunwald E. Loscalzo J. Edema. En: JamesonJ. Fauci A. Kasper D. Hauser S. Longo D.Loscalzo J, editors. Harrison. Principios deMedicina Interna. 20a ed. CDMX: McGraw Hill;2018.

  13. Mount D. Trastornos hidroelectrolíticos. En:Jameson J. Fauci A. Kasper D. Hauser S. LongoD. Loscalzo J, editors. Harrison. Principios deMedicina Interna. 20a ed. CDMX: McGraw Hill;2018.

  14. Corey K. Friedman L. Distensión abdominaly ascitis. En: Jameson J. Fauci A. KasperD. Hauser S. Longo D. Loscalzo J, editors.Harrison. Principios de Medicina Interna. 20aed. CDMX: McGraw Hill; 2018.

  15. Kipps E. Tan DS. Kaye SB. Meeting thechallenge of ascites in ovarian cancer: newavenues for therapy and research. Nat RevCancer. 2013; 13:273-282.

  16. Nagy JA. Herzberg KT. Dvorak JM. Dvorak HF.Pathogenesis of malignant ascites formation:initiating events that lead to fluid accumulation.Cancer Res. 1993; 53:2631-2643.

  17. Senger DR. Galli SJ. Dvorak AM. Perruzzi CA.Harvey VS. Dvorak HF. Tumor cells secrete avascular permeability factor that promotesaccumulation of ascites fluid. Science. 1983;219:983-985.

  18. Esser S. Lampugnani MG. Corada M. DejanaE. Risau W. Vascular endothelial growth factorinduces VE-cadherin tyrosine phosphorylationin endothelial cells. J Cell Sci. 1998; 111:1853-1865.

  19. Zebrowski BK. Liu W. Ramirez K. Akagi Y.Mills GB. Ellis LM. Markedly elevated levelsof vascular endothelial growth factor inmalignant ascites. Ann Surg Oncol. 1999;6:373-378.

  20. Herr D. Sallmann A. Bekes I. Konrad R. HolzheuI. Kreienberg R. et al. VEGF induces ascitesin ovarian cancer patients via increasingperitoneal permeability by downregulation ofClaudin 5. Gynecol Oncol. 2012; 127:210-

  21. 216.21. Sowter HM. Corps AN. Smith SK. Hepatocytegrowth factor (HGF) in ovarian epithelialtumour fluids stimulates the migration ofovarian carcinoma cells. Int J Cancer. 1999;83:476-480.

  22. Pua TL. Wang FQ. Fishman DA. Roles of LPA inovarian cancer development and progression.Future Oncol. 2009; 5:1659-1673.

  23. Hu YL. Tee MK. Goetzl EJ. Auersperg N. MillsGB. Ferrara N. et al. Lysophosphatidic acidinduction of vascular endothelial growth factorexpression in human ovarian cancer cells. JNatl Cancer Inst. 2001; 93:762-768.

  24. Santin AD. Hermonat PL. Ravaggi A. CannonMJ. Pecorelli S. Parham GP. Secretion ofvascular endothelial growth factor in ovariancancer. Eur J Gynaecol Oncol. 1999; 20:177-181.

  25. Hikita S. Yotsumoto F. Fukami T. Fumaki T.Horiuchi S. Sanui A. et al. Assessment ofHB-EGF levels in peritoneal fluid and serumof ovarian cancer patients using ELISA.Anticancer Res. 2011; 31:2553-2559.

  26. Sadłecki P. Walentowicz-Sadłecka M.Szymański W. Grabiec M. [Comparison ofVEGF, IL-8 and beta-FGF concentrations inthe serum and ascites of patients with ovariancancer]. Ginekol Pol. 2011; 82:498-502.

  27. Saltzman AK. Hartenbach EM. Carter JR.Contreras DN. Twiggs LB. Carson LF. et al.Transforming growth factor-alpha levels in theserum and ascites of patients with advancedepithelial ovarian cancer. Gynecol ObstetInvest. 1999; 47:200-204.

  28. Santin AD. Bellone S. Ravaggi A. Roman J.Smith CV. Pecorelli S. et al. Increased levelsof interleukin-10 and transforming growthfactor-beta in the plasma and ascitic fluid ofpatients with advanced ovarian cancer. BJOG.2001; 108:804-808.

  29. Mills GB. May C. McGill M. Roifman CM. MellorsA. A putative new growth factor in ascitic fluidfrom ovarian cancer patients: identification,characterization, and mechanism of action.Cancer Res. 1988; 48:1066-1071.

  30. Penson RT. Kronish K. Duan Z. Feller AJ. StarkP. Cook SE. et al. Cytokines IL-1beta, IL-2,IL-6, IL-8, MCP-1, GM-CSF and TNFalpha inpatients with epithelial ovarian cancer andtheir relationship to treatment with paclitaxel.Int J Gynecol Cancer. 2000; 10:33-41.

  31. Mills GB. May C. Hill M. Campbell S. ShawP. Marks A. Ascitic fluid from human ovariancancer patients contains growth factorsnecessary for intraperitoneal growth of humanovarian adenocarcinoma cells. J Clin Invest.1990; 86:851-855.

  32. Matte I. Lane D. Laplante C. Rancourt C. PicheA. Profiling of cytokines in human epithelialovarian cancer ascites. Am J Cancer Res.2012; 2:566-580.

  33. Batchu RB. Gruzdyn OV. Kolli BK. Dachepalli R.Umar PS. Rai SK. et al. IL-10 Signaling in theTumor Microenvironment of Ovarian Cancer.Adv Exp Med Biol. 2021; 1290:51-65.

  34. Kryczek I. Grybos M. Karabon L. Klimczak A.Lange A. IL-6 production in ovarian carcinomais associated with histiotype and biologicalcharacteristics of the tumour and influenceslocal immunity. Br J Cancer. 2000; 82:621-628.

  35. Huang S. Robinson JB. Deguzman A. BucanaCD. Fidler IJ. Blockade of nuclear factorkappaBsignaling inhibits angiogenesis andtumorigenicity of human ovarian cancercells by suppressing expression of vascularendothelial growth factor and interleukin 8.Cancer Res. 2000; 60:5334-5339.

  36. Lane D. Matte I. Rancourt C. Piche A.Prognostic significance of IL-6 and IL-8 asciteslevels in ovarian cancer patients. BMC Cancer.2011; 11:210.

  37. Plante M. Rubin SC. Wong GY. Federici MG.Finstad CL. Gastl GA. Interleukin-6 level inserum and ascites as a prognostic factor inpatients with epithelial ovarian cancer. Cancer.1994; 73:1882-1888.

  38. Moradi MM. Carson LF. Weinberg B. Haney AF.Twiggs LB. Ramakrishnan S. Serum and asciticfluid levels of interleukin-1, interleukin-6,and tumor necrosis factor-alpha in patientswith ovarian epithelial cancer. Cancer. 1993;72:2433-2440.

  39. Kolomeyevskaya N. Eng KH. Khan AN.Grzankowski KS. Singel KL. Moysich K. et al.Cytokine profiling of ascites at primary surgeryidentifies an interaction of tumor necrosisfactor-α and interleukin-6 in predicting reducedprogression-free survival in epithelial ovariancancer. Gynecol Oncol. 2015; 138:352-357.

  40. Wang W. Wu J. Mukherjee A. He T. Wang XY.Ma Y. et al. Lysophosphatidic acid inducestumor necrosis factor-alpha to regulate apro-inflammatory cytokine network in ovariancancer. FASEB J. 2020; 34:13935-13948.

  41. Monavarian M. Elhaw AT. Tang PW. JavedZ. Shonibare Z. Scalise CB. et al. Emergingperspectives on growth factor metabolicrelationships in the ovarian cancer ascitesenvironment. Semin Cancer Biol. 2022;S1044-579X(22)00060.

  42. Thibault B. Castells M. Delord JP. Couderc B.Ovarian cancer microenvironment: implicationsfor cancer dissemination and chemoresistanceacquisition. Cancer Metastasis Rev. 2014;33:17-39.

  43. Szender JB. Emmons T. Belliotti S. DicksonD. Khan A. Morrell K. et al. Impact of ascitesvolume on clinical outcomes in ovariancancer: A cohort study. Gynecol Oncol. 2017;146:491-497.

  44. Ford CE. Werner B. Hacker NF. Warton K. Theuntapped potential of ascites in ovarian cancerresearch and treatment. Br J Cancer. 2020;123:9-16.

  45. Rosenberg SM. Palliation of malignant ascites.Gastroenterol Clin North Am. 2006; 35:189-99, xi.

  46. Smolle E. Taucher V. Haybaeck J. Malignantascites in ovarian cancer and the role oftargeted therapeutics. Anticancer Res. 2014;34:1553-1561.

  47. Monk BJ. Pujade-Lauraine E. Burger RA.Integrating bevacizumab into the managementof epithelial ovarian cancer: the controversy offront-line versus recurrent disease. Ann Oncol.2013; 24 Suppl 10:x53-x58.

  48. Aghajanian C. Goff B. Nycum LR. Wang YV.Husain A. Blank SV. Final overall survival andsafety analysis of OCEANS, a phase 3 trial ofchemotherapy with or without bevacizumabin patients with platinum-sensitive recurrentovarian cancer. Gynecol Oncol. 2015; 139:10-16.

  49. Pujade-Lauraine E. Hilpert F. Weber B. ReussA. Poveda A. Kristensen G. et al. Bevacizumabcombined with chemotherapy for platinumresistantrecurrent ovarian cancer: TheAURELIA open-label randomized phase IIItrial. J Clin Oncol. 2014; 32:1302-1308.

  50. Burger RA. Brady MF. Bookman MA. FlemingGF. Monk BJ. Huang H. et al. Incorporationof bevacizumab in the primary treatment ofovarian cancer. N Engl J Med. 2011; 365:2473-2483.

  51. Perren TJ. Swart AM. Pfisterer J. LedermannJA. Pujade-Lauraine E. Kristensen G. et al. Aphase 3 trial of bevacizumab in ovarian cancer.N Engl J Med. 2011; 365:2484-2496.

  52. Tewari KS. Burger RA. Enserro D. NorquistBM. Swisher EM. Brady MF. et al. Final OverallSurvival of a Randomized Trial of Bevacizumabfor Primary Treatment of Ovarian Cancer. J ClinOncol. 2019; 37:2317-2328.

  53. Saini U. Naidu S. ElNaggar AC. Bid HK. WallbillichJJ. Bixel K. et al. Elevated STAT3 expressionin ovarian cancer ascites promotes invasionand metastasis: a potential therapeutic target.Oncogene. 2017; 36:168-181.

  54. Wei X. Liu Y. Gong C. Ji T. Zhou X. Zhang T. etal. Targeting Leptin as a Therapeutic Strategyagainst Ovarian Cancer Peritoneal Metastasis.Anticancer Agents Med Chem. 2017; 17:1093-1101.




2020     |     www.medigraphic.com